Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28.5M
-
Number of holders
-
91
-
Total 13F shares, excl. options
-
56.6M
-
Shares change
-
-9.6K
-
Total reported value, excl. options
-
$202M
-
Value change
-
-$4.27M
-
Put/Call ratio
-
0.15
-
Number of buys
-
49
-
Number of sells
-
-40
-
Price
-
$3.56
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q3 2021
107 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q3 2021.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 91 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.6M shares
.
Largest 10 shareholders include BROADWOOD CAPITAL INC (17.3M shares), PURA VIDA INVESTMENTS, LLC (12.2M shares), BlackRock Inc. (4.37M shares), VANGUARD GROUP INC (3.88M shares), ORBIMED ADVISORS LLC (2.86M shares), Defender Capital, LLC. (1.96M shares), Nuveen Asset Management, LLC (1.41M shares), STATE STREET CORP (1.4M shares), Schonfeld Strategic Advisors LLC (1.27M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.16M shares).
This table shows the top 91 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.